Travere Therapeutics, Inc.
TVTX
Pozycja w akcjach
#3580
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies... Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
Cena akcji
$50.52
Ostatnia synchronizacja: 2026-10-19
Kapitalizacja rynkowa
$4.76B
Zmiana (1 dzień)
1.85%
Zmiana (1 rok)
81.14%
Kraj
US
Handel Travere Therapeutics, Inc. (TVTX)
Kategoria
Healthcare
Zyski dla Travere Therapeutics, Inc. (TVTX)
Zyski w Jun 2026 TTM: $-67.07M
Według najnowszych raportów finansowych Travere Therapeutics, Inc., obecny zysk firmy wynosi $-67.07M. W roku 2023 firma osiągnęła zysk w wysokości $-376.11M, spadek w porównaniu do zysku z roku 2022, który wynosił $-331.16M. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Travere Therapeutics, Inc. od 2009 do 2026
Zyski na koniec każdego roku
| Rok | Zyski | Zmień |
|---|---|---|
| 2026 (TTM) | $-67.07M | -79.07% |
| 2024 | $-320.51M | -14.78% |
| 2023 | $-376.11M | 13.58% |
| 2022 | $-331.16M | 52.69% |
| 2021 | $-216.88M | 14.88% |
| 2020 | $-188.79M | 28.91% |
| 2019 | $-146.45M | 43.76% |
| 2018 | $-101.87M | 74.54% |
| 2017 | $-58.36M | 1.36% |
| 2016 | $-57.58M | -154.60% |
| 2015 | $105.47M | -193.01% |
| 2014 | $-113.40M | 236.02% |
| 2013 | $-33.75M | 11.22% |
| 2012 | $-30.34M | 166,022.06% |
| 2009 | $-18.27K | 0.00% |
Zyski podobnych firm lub konkurentów
| Firma | Zyski | Różnica w zyskach | Kraj |
|---|---|---|---|
| $5.27B | -7,964.30% |
US
|
|
| $-3.09B | 4,502.38% |
US
|
|
| $-4.02B | 5,887.71% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -3,008.21% |
NL
|
